AAPL295.18+5.82 (+2.01%) ▲|ABBV249.56-2.08 (-0.83%) ▼|ABT92.85+2.11 (+2.33%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE212.61+7.59 (+3.70%) ▲|AMAT663.31-59.69 (-8.26%) ▼|AMD551.15-29.77 (-5.12%) ▼|AMGN360.80-1.32 (-0.36%) ▼|AMT165.55+1.98 (+1.21%) ▲|AMZN241.81+3.47 (+1.46%) ▲|AVGO370.59-7.16 (-1.90%) ▼|AXP348.72+10.47 (+3.10%) ▲|BA217.87+1.40 (+0.65%) ▲|BAC58.23+1.25 (+2.19%) ▲|BKNG184.71+6.47 (+3.63%) ▲|BLK978.17+16.61 (+1.73%) ▲|BMY56.66-0.97 (-1.67%) ▼|BNY146.74+2.13 (+1.47%) ▲|BRK-B503.15+2.76 (+0.55%) ▲|C140.73+0.77 (+0.55%) ▲|CAT1,019.34-45.56 (-4.28%) ▼|CL92.49+0.81 (+0.88%) ▲|CMCSA24.16-0.39 (-1.59%) ▼|COF204.94+4.32 (+2.15%) ▲|COP103.74-0.22 (-0.21%) ▼|COST926.70-8.77 (-0.94%) ▼|CRM164.94+8.28 (+5.28%) ▲|CSCO116.33-1.13 (-0.96%) ▼|CVS104.11+0.66 (+0.63%) ▲|CVX166.32+0.56 (+0.34%) ▲|DE631.49-2.84 (-0.45%) ▼|DHR194.76+4.28 (+2.24%) ▲|DIS97.04+0.79 (+0.82%) ▲|DUK126.18-0.40 (-0.32%) ▼|EMR142.47-0.68 (-0.48%) ▼|FDX315.03+1.90 (+0.61%) ▲|GD364.11+9.87 (+2.79%) ▲|GE375.80+2.07 (+0.55%) ▲|GEV1,153.80-21.06 (-1.79%) ▼|GILD126.20-0.15 (-0.11%) ▼|GM76.53-0.56 (-0.72%) ▼|GOOG356.33+3.00 (+0.85%) ▲|GOOGL359.45+2.08 (+0.58%) ▲|GS1,024.23+12.86 (+1.27%) ▲|HD356.34+3.66 (+1.04%) ▲|HON224.19+0.29 (+0.13%) ▲|IBM293.10+11.89 (+4.23%) ▲|INTC129.30-10.33 (-7.40%) ▼|INTU272.00+11.00 (+4.21%) ▲|ISRG404.99+7.31 (+1.84%) ▲|JNJ252.34-1.63 (-0.64%) ▼|JPM334.34+7.01 (+2.14%) ▲|KO81.76+0.49 (+0.60%) ▲|LIN536.04+17.10 (+3.30%) ▲|LLY1,191.20-8.24 (-0.69%) ▼|LMT521.48+12.02 (+2.36%) ▲|LOW225.28+4.79 (+2.17%) ▲|LRCX396.34-36.99 (-8.54%) ▼|MA528.55+14.95 (+2.91%) ▲|MCD270.44+0.13 (+0.05%) ▲|MDLZ59.17+1.33 (+2.29%) ▲|MDT79.40+1.17 (+1.50%) ▲|META618.43+55.14 (+9.79%) ▲|MMM161.68-0.23 (-0.14%) ▼|MO71.96+0.01 (+0.01%) ▲|MRK126.59-1.91 (-1.49%) ▼|MS211.51+2.47 (+1.18%) ▲|MSFT384.67+11.65 (+3.12%) ▲|MU1,053.73-100.57 (-8.71%) ▼|NEE86.95-0.82 (-0.93%) ▼|NFLX73.39+1.99 (+2.78%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.65+6.37 (+6.42%) ▲|NVDA196.89-3.20 (-1.60%) ▼|ORCL145.11-1.44 (-0.98%) ▼|PEP140.05+4.65 (+3.43%) ▲|PFE23.94-0.15 (-0.60%) ▼|PG146.37-0.27 (-0.18%) ▼|PLTR127.19+10.52 (+9.02%) ▲|PM178.43-2.48 (-1.37%) ▼|QCOM185.52+0.73 (+0.39%) ▲|RTX191.39+1.66 (+0.87%) ▲|SBUX101.57-0.63 (-0.61%) ▼|SCHW94.40+2.13 (+2.31%) ▲|SO95.79+0.08 (+0.08%) ▲|SPG221.82-1.84 (-0.82%) ▼|T20.64-0.06 (-0.29%) ▼|TMO520.60+19.24 (+3.84%) ▲|TMUS172.53+4.80 (+2.86%) ▲|TSLA429.34+8.74 (+2.08%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.35+1.19 (+1.65%) ▲|UNH421.65+6.02 (+1.45%) ▲|UNP276.15+4.15 (+1.53%) ▲|UPS109.83+2.33 (+2.17%) ▲|USB61.98+1.58 (+2.62%) ▲|V352.39+9.30 (+2.71%) ▲|VZ42.08-0.27 (-0.63%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.05-5.21 (-4.60%) ▼|XOM136.85+0.13 (+0.10%) ▲|AAPL295.18+5.82 (+2.01%) ▲|ABBV249.56-2.08 (-0.83%) ▼|ABT92.85+2.11 (+2.33%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE212.61+7.59 (+3.70%) ▲|AMAT663.31-59.69 (-8.26%) ▼|AMD551.15-29.77 (-5.12%) ▼|AMGN360.80-1.32 (-0.36%) ▼|AMT165.55+1.98 (+1.21%) ▲|AMZN241.81+3.47 (+1.46%) ▲|AVGO370.59-7.16 (-1.90%) ▼|AXP348.72+10.47 (+3.10%) ▲|BA217.87+1.40 (+0.65%) ▲|BAC58.23+1.25 (+2.19%) ▲|BKNG184.71+6.47 (+3.63%) ▲|BLK978.17+16.61 (+1.73%) ▲|BMY56.66-0.97 (-1.67%) ▼|BNY146.74+2.13 (+1.47%) ▲|BRK-B503.15+2.76 (+0.55%) ▲|C140.73+0.77 (+0.55%) ▲|CAT1,019.34-45.56 (-4.28%) ▼|CL92.49+0.81 (+0.88%) ▲|CMCSA24.16-0.39 (-1.59%) ▼|COF204.94+4.32 (+2.15%) ▲|COP103.74-0.22 (-0.21%) ▼|COST926.70-8.77 (-0.94%) ▼|CRM164.94+8.28 (+5.28%) ▲|CSCO116.33-1.13 (-0.96%) ▼|CVS104.11+0.66 (+0.63%) ▲|CVX166.32+0.56 (+0.34%) ▲|DE631.49-2.84 (-0.45%) ▼|DHR194.76+4.28 (+2.24%) ▲|DIS97.04+0.79 (+0.82%) ▲|DUK126.18-0.40 (-0.32%) ▼|EMR142.47-0.68 (-0.48%) ▼|FDX315.03+1.90 (+0.61%) ▲|GD364.11+9.87 (+2.79%) ▲|GE375.80+2.07 (+0.55%) ▲|GEV1,153.80-21.06 (-1.79%) ▼|GILD126.20-0.15 (-0.11%) ▼|GM76.53-0.56 (-0.72%) ▼|GOOG356.33+3.00 (+0.85%) ▲|GOOGL359.45+2.08 (+0.58%) ▲|GS1,024.23+12.86 (+1.27%) ▲|HD356.34+3.66 (+1.04%) ▲|HON224.19+0.29 (+0.13%) ▲|IBM293.10+11.89 (+4.23%) ▲|INTC129.30-10.33 (-7.40%) ▼|INTU272.00+11.00 (+4.21%) ▲|ISRG404.99+7.31 (+1.84%) ▲|JNJ252.34-1.63 (-0.64%) ▼|JPM334.34+7.01 (+2.14%) ▲|KO81.76+0.49 (+0.60%) ▲|LIN536.04+17.10 (+3.30%) ▲|LLY1,191.20-8.24 (-0.69%) ▼|LMT521.48+12.02 (+2.36%) ▲|LOW225.28+4.79 (+2.17%) ▲|LRCX396.34-36.99 (-8.54%) ▼|MA528.55+14.95 (+2.91%) ▲|MCD270.44+0.13 (+0.05%) ▲|MDLZ59.17+1.33 (+2.29%) ▲|MDT79.40+1.17 (+1.50%) ▲|META618.43+55.14 (+9.79%) ▲|MMM161.68-0.23 (-0.14%) ▼|MO71.96+0.01 (+0.01%) ▲|MRK126.59-1.91 (-1.49%) ▼|MS211.51+2.47 (+1.18%) ▲|MSFT384.67+11.65 (+3.12%) ▲|MU1,053.73-100.57 (-8.71%) ▼|NEE86.95-0.82 (-0.93%) ▼|NFLX73.39+1.99 (+2.78%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.65+6.37 (+6.42%) ▲|NVDA196.89-3.20 (-1.60%) ▼|ORCL145.11-1.44 (-0.98%) ▼|PEP140.05+4.65 (+3.43%) ▲|PFE23.94-0.15 (-0.60%) ▼|PG146.37-0.27 (-0.18%) ▼|PLTR127.19+10.52 (+9.02%) ▲|PM178.43-2.48 (-1.37%) ▼|QCOM185.52+0.73 (+0.39%) ▲|RTX191.39+1.66 (+0.87%) ▲|SBUX101.57-0.63 (-0.61%) ▼|SCHW94.40+2.13 (+2.31%) ▲|SO95.79+0.08 (+0.08%) ▲|SPG221.82-1.84 (-0.82%) ▼|T20.64-0.06 (-0.29%) ▼|TMO520.60+19.24 (+3.84%) ▲|TMUS172.53+4.80 (+2.86%) ▲|TSLA429.34+8.74 (+2.08%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.35+1.19 (+1.65%) ▲|UNH421.65+6.02 (+1.45%) ▲|UNP276.15+4.15 (+1.53%) ▲|UPS109.83+2.33 (+2.17%) ▲|USB61.98+1.58 (+2.62%) ▲|V352.39+9.30 (+2.71%) ▲|VZ42.08-0.27 (-0.63%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.05-5.21 (-4.60%) ▼|XOM136.85+0.13 (+0.10%) ▲|
33.9 C
New York
Wednesday, July 1, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

Intrinsic Therapeutics, Inc. Announces That ISASS Has Issued Updated 2025 Recommendations and Coverage Criteria for Barricaid Bone-Anchored Annular Closure

BOSTON, June 19, 2025 /PRNewswire/ -- Intrinsic Therapeutics, a medical technology company committed to redefining the standard of care for lumbar discectomy patients with...

New Study Data on Chemo-Immunotherapy Approach Using the ELIAS Cancer Immunotherapy (ECI®) to Treat Bone Cancer in Dogs Demonstrates Improved Outcomes

LENEXA, Kan., June 19, 2025 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced interim results from an ongoing clinical...

CD5 Targeted Therapies CD5 Targeting CAR T Cell Therapy Clinical Trials Market Insight 2025

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research 
First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research

RWJBarnabas Health, Rutgers Cancer Institute, Tufts Medical Center, and The University of Manchester Develop First Risk Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma

Research Published in NEJM Evidence and presented at the International Conference on Malignant Lymphoma NEW BRUNSWICK, N.J. and BOSTON, June 19, 2025 /PRNewswire/ -- Researchers from...

Risk Analytics Market is Poised to Hit $91.33 Billion, Globally, by 2030 Amid Rising Threat Complexity – Exclusive Report by The Research Insights

CHICAGO, June 19, 2025 /PRNewswire/ -- The Risk Analytics Market is projected to be valued at USD 44.55 billion in 2024 and reach USD 91.33 billion by 2030, growing at...

Risk Analytics Market is Poised to Hit $91.33 Billion, Globally, by 2030 Amid Rising Threat Complexity – Exclusive Report by The Research Insights

CHICAGO, June 19, 2025 /PRNewswire/ -- The Risk Analytics Market is projected to be valued at USD 44.55 billion in 2024 and reach USD 91.33 billion by 2030, growing at...

Birch Allergy Market Forecast Report 2025-2035: Innovations in Immunotherapy Transforming Birch Allergy Treatment

The global birch allergy market is experiencing robust growth due to increasing cases of allergic rhinitis from birch pollen and advancements in treatments like immunotherapy. Rising awareness and improved healthcare infrastructures in key regions such as the U.S., U.K., and Germany drive market expansion. Key therapies, including antihistamines and sublingual immunotherapy, are evolving alongside biologics and targeted treatments for severe cases. Despite challenges like high costs and regulatory hurdles, strategic partnerships and R&D in biologics are shaping the market. Ongoing innovations and digital health integrations are set to enhance patient outcomes globally. 
The global birch allergy market is experiencing robust growth due to increasing cases of allergic rhinitis from birch pollen and advancements in treatments like immunotherapy. Rising awareness and improved healthcare infrastructures in key regions such as the U.S., U.K., and Germany drive market expansion. Key therapies, including antihistamines and sublingual immunotherapy, are evolving alongside biologics and targeted treatments for severe cases. Despite challenges like high costs and regulatory hurdles, strategic partnerships and R&D in biologics are shaping the market. Ongoing innovations and digital health integrations are set to enhance patient outcomes globally.

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

If approved, Zemcelpro® is expected to:increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromesbe...

Pharmaceutical Membrane Filters Market Size to Surpass USD 20.05 Billion by 2031, at 13.1% CAGR: The Insight Partners

NEW YORK, June 19, 2025 /PRNewswire/ -- According to a new, comprehensive report from The Insight Partners, the pharmaceutical membrane filters market is growing...

Kansas State University Veterinary Health Center Adopts Instinct EMR, Retires Legacy System

PHILADELPHIA, June 19, 2025 (GLOBE NEWSWIRE) -- The Veterinary Health Center at Kansas State University (K-State’s VHC), a leading veterinary teaching hospital in the United States, has transitioned to Instinct EMR, a cloud-based electronic medical record system built for the complexity of modern veterinary care.

Commure Raises $200 Million in Growth Financing from General Catalyst’s CVF to Accelerate AI-Powered RCM Platform

SAN FRANCISCO, June 19, 2025 (GLOBE NEWSWIRE) -- Commure, the fast-growing enterprise AI healthcare technology company powering next-generation infrastructure for providers, today announced it has secured $200 million in growth financing from General Catalyst’s Customer Value Fund (CVF). The funding will be used to meet surging demand for Commure’s full-stack AI platform, which spans revenue cycle management (RCM), Ambient AI clinical documentation and workflows, and practice management solutions.

Theranica to Present Three Real-World Evidence Studies at AHS Scientific Meeting Highlighting the Impact of the Nerivio® REN Wearable on Migraine Treatment

Theranica is presenting three real-world evidence studies at the American Headache Society (AHS) 67th Annual Scientific Congress.

Memo Therapeutics AG to Present Interim Phase II Results of Potravitug for the Treatment of BKV Infection in Kidney Transplant Recipients in a Late...

PRESS RELEASE

Pharmacy Times® Releases 2025 OTC Guide® Featuring Brands Most Recommended by Pharmacists Nationwide

Trusted consumer resource now in its 29th year highlights the top over the counter (OTC) products across 149 categories 
Trusted consumer resource now in its 29th year highlights the top over the counter (OTC) products across 149 categories

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers